FOSUN PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

make any statement and expressly disclaim any liability for any damages whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

assumes no responsibility for any failure.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 02196)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Tenth Annual Report" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange.

Announcement of Resolutions of the Thirty-third Meeting of the Board of Directors (Extraordinary Meeting)" is for reference only.

By order of the board of directors Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Chairman

Chen Yuqing

China, Shanghai

July 1, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the Company The non-executive directors of the company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the company are Mr. Yu Zishan, Mr. Wang Quandi, and Mr. Chen Mr. Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

*For identification only

Securities code: 600196 Stock abbreviation: Fosun Pharma Number: Lin 2026-093

Shanghai Shanghai Fufu Xingxing Medical and Pharmaceutical ((Group)) Co., Ltd.

Announcement of Resolutions of the 333rd Meeting of the 10th Session of the Board of Directors ((Extraordinary Meeting))

The Board of Directors of the Company and all directors hereby certify that the contents of this announcement do not contain any false or misleading statements.

There may be any serious omissions or omissions, and we shall not be held legally responsible for the authenticity, accuracy and completeness of the content. .

The third session of the 10th Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company")

The thirteenth meeting (extraordinary meeting) was held on July 1, 2026. All directors attended the meeting by communication

discussion. The convening of this meeting complied with the Company Law of the People's Republic of China, other relevant laws and regulations and the Shanghai Complex The provisions of the Articles of Association of Xing Pharmaceutical (Group) Co., Ltd. The meeting reviewed and reached the following resolutions:

The motion on the reform and recruitment of current senior management personnel was reviewed and approved. .

In order to further promote the implementation of the innovation strategy of the Group (i.e. the Company and its holding subsidiaries/units, the same below), the company has

CEO Mr. Liu Yi nominated and agreed to promote and appoint Mr. Xingli Wang as the president of the company (this change

(Served as Co-President of the Company before the appointment), and the term of the post after promotion will be from July 1, 2026 to the current session of the Board of Directors. The term ends on the expiration date; from the same date, the CEO, Mr. Liu Yi, will no longer serve as the president of the company.

The Board of Directors also expresses its gratitude to Mr. Liu Yi for his work during his tenure as President of the Company.

Voting results: 12 votes in favor, 0 votes against, and 0 abstentions.

This matter has also been reviewed and approved by the Nomination Committee of the Board of Directors.

Please see the attachment for Mr. Xingli Wang’s resume.

Announcement is hereby made.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

board of directors July 1, 2026

Attachment: Resume

Mr. Xingli Wang, born in December 1962, American nationality, currently president of the company, innovative drug CEO of the business unit, chairman of the global R&D center; and serves as director of several holding subsidiaries of the company

Positions include Shanghai Fuhong Hanlin Biotech Co., Ltd., a company listed on The Stock Exchange of Hong Kong Limited

Ltd. (stock code: 02696) as a non-executive director. Mr. Xingli Wang joined in January 2023

Joined the Group and served as the company’s executive president from January 2023 to June 2025. From June 2025 to

In June 2026, he was appointed as the co-president of the company, and in July 2026, he was appointed as the president of the company. Before joining our group, Mr. Xingli Wang successively studied at The University of New South Wales (New South Wales, Australia).

University of New South Wales (hereinafter referred to as "UNSW") for postdoctoral research in cardiovascular medicine.

Prince of Wales Hospital (Prince of Wales Hospital in Sydney) conducts clinical residency training,

He is a senior lecturer in cardiovascular medicine at the University of New South Wales and a professor at Baylor College of Medicine (USA).

Baylor College of Medicine) as director of cardiothoracic surgery research and tenured professor, at Schering-Plough Corporation (formerly a company listed on the New York Stock Exchange, stock code: SGP; merged into Merck in 2009

& Co., Inc.) as project medical director; from October 2010 to May 2022 on the New York Stock Exchange

Novartis AG (stock code: NVS), a company listed on the Exchange, has successively served as project section chief and global project clinical director.

He is currently the head of Novartis Global Drug R&D (China) and the general manager of the Biomedical Research Institute (China).

Mr. Xingli Wang holds a bachelor's degree in medicine from Shandong Medical College (now merged into Shandong University), He holds a doctorate in cardiovascular medicine from the University of Wales and holds an Australian medical license.